

cont. muscles induced by the administration of substance P, or (iii) a combination thereof, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically-acceptable medium therefor.

D2 28. (Amended) The method of Claim 115, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

29. (Amended) The method of Claim 115, wherein said substance P antagonist is a peptide.

30. (Amended) The method of Claim 115, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

31. (Amended) The method of Claim 115, wherein said substance P antagonist is selected from the group consisting of 2-tricycyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

32. (Amended) The method of Claim 115, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

D³
34. (Amended) The method of Claim 115, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

35. (Amended) The method of Claim 115, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatories, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

36. (Amended) The method of Claim 115, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorohydrate, non-steroidal anti-parasitics, and anti-inflammatory agents.

37. (Amended) The method of Claim 115, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave

D³
cont.
lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

D⁴
40. (Amended) The method of Claim 115, wherein said substance P antagonist is contained in an emulsion.

D⁵
45. (Amended) The method of Claim 115, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

46. (Amended) The method of Claim 115, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

D⁶
47. (Twice Amended) The method of Claim 114, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

D⁷
49. (Amended) The method of Claim 115, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.


D⁸
51. (Amended) The method of Claim 115, wherein said substance P antagonist is contained in a cosmetically-acceptable medium.

D⁹
53. (Amended) The method of Claim 115, wherein said sensitive skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

D¹⁰
56. (Amended) The method of Claim 117, wherein said substance P antagonist is a compound that (i) reduces the extravasation of plasma through the vascular wall caused by capsaicin or by antidromic nerve excitation, or (ii) inhibits the contraction of the smooth muscles induced by the administration of substance P, or (iii) a combination thereof, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically-acceptable medium therefor.

D¹¹
57. (Amended) The method of Claim 117, wherein the method of treatment [or prevention] of sensitive, but not allergic, skin alleviates or prevents at least one neurogenic manifestation selected from the group consisting of skin irritation, desquamation, erythema, side effects of dysesthesia, side effects of overheating, and skin pruritus.


58. (Amended) The method of Claim 117, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

59. (Amended) The method of Claim 117, wherein said substance P antagonist is a peptide.

60. (Amended) The method of Claim 117, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

61. (Amended) The method of Claim 117, wherein said substance P antagonist is selected from the group consisting of 2-tricycyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

62. (Amended) The method of Claim 117, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

64. (Amended) The method of Claim 117, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

65. (Amended) The method of Claim 117, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatories, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

66. (Amended) The method of Claim 117, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorohydrate, non-steroidal anti-parasitics, and anti-inflammatory agents.

67. (Amended) The method of Claim 117, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

70. (Amended) The method of Claim 117, wherein said substance P antagonist is contained in an emulsion.

D¹³
75. (Amended) The method of Claim 117, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

76. (Amended) The method of Claim 117, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

D¹⁴
77. (Twice Amended) The method of Claim 117, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

D¹⁵
79. (Amended) The method of Claim 117, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.

D¹⁶
81. (Amended) The method of Claim 117, wherein said substance P antagonist is contained in a cosmetically-acceptable medium.

D17
83. (Amended) The method of Claim 117, wherein said sensitive, but not allergic, skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

84. (Amended) The method of Claim 117, wherein said at least one symptom is observed between 3 and 20 minutes after capsaicin application.

D18
86. (Amended) The method of Claim 119, wherein said substance P antagonist is a compound that (i) reduces the extravasation of plasma through the vascular wall caused by capsaicin or by antidromic nerve excitation, or (ii) inhibits the contraction of the smooth muscles induced by the administration of substance P, or (iii) a combination thereof, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically-acceptable medium therefor.

87. (Amended) The method of Claim 119, wherein the method of treatment [or prevention] of capsaicin-sensitive skin alleviates or prevents at least one neurogenic manifestation selected from the group consisting of skin irritation, desquamation, erythema, side effects of dysesthesia, side effects of overheating, and skin pruritus.

88. (Amended) The method of Claim 119, wherein the substance P antagonist is a nitrogen-containing heterocyclic compound.

89. (Amended) The method of Claim 119, wherein said substance P antagonist is a peptide.

D18
cont.
90. (Amended) The method of Claim 119, wherein said substance P antagonist is a peptide selected from the group consisting of sendide and spantide II.

91. (Amended) The method of Claim 119, wherein said substance P antagonist is selected from the group consisting of 2-tricyclyl-2-aminoethane, spirolactame, quinuclidine, azacyclic, aminopyrrolidine, piperidine, aminoazeheterocyclic and isoindole compounds.

92. (Amended) The method of Claim 119, wherein the substance P antagonist is contained in an amount ranging from between 0.000001 to 5 percent by weight of the total weight of the composition.

D19
94. (Amended) The method of Claim 119, wherein said substance P antagonist is administered in a topically administrable form selected from the group consisting of aqueous and hydroalcoholic solutions, water-in-oil and oil-in-water emulsions, microemulsions, aqueous gels, anhydrous gels, serums and vesicular dispersions.

95. (Amended) The method of Claim 119, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of

anti-bacterials, anti-parasitics, anti-fungals, anti-inflammatories, anti-pruriginous agents, anesthetics, anti-virals, keratolytic agents, anti-free radical agents, anti-seborrheal agents, dandruff-fighting agents, acne-fighting agents, skin differentiating modulating agents, skin proliferation modulating agents, and skin pigmentation modulating agents.

D¹⁹
Cov

96. (Amended) The method of Claim 119, wherein said substance P antagonist is co-administered with at least one agent selected from the group consisting of lidocaine, chlorohydrate, non-steroidal anti-parasitics, and anti-inflammatory agents.

97. (Amended) The method of Claim 119, wherein said substance P antagonist is contained in a cosmetic or dermatological composition selected from the group consisting of cleansing creams, make-up removal creams, foundation creams, sunscreen creams, liquid foundations, make-up removal lotions, skin-care lotions, sunscreen lotions, skin-care gels, skin-care foams, tanning lotions, bath preparations, after-shave gels, after-shave lotions, depilatory creams, insect sting compositions, soaps, cleansing bars, aerosol compositions, hair care compositions, and mouth care compositions.

D²⁰

100. (Amended) The method of Claim 119, wherein said substance P antagonist is contained in an emulsion.

D²¹

105. (Amended) The method of Claim 119, wherein said substance P antagonist is administered together with at least one additive selected from the group consisting of a

water-absorbent or lipophilic gelling agent, water-absorbent or lipophilic active ingredient, preservative, antioxidant, solvent, perfume, filler, screen and coloring substance.

D²¹
106. (Amended) The method of Claim 119, wherein said substance P antagonist is administered together with at least one oil selected from the group consisting of a mineral oil, vegetable oil, animal oil, synthetic oil, silicone-containing oil, and a fluorinated oil.

D²²
107. (Twice Amended) The method of Claim 119, wherein said substance P antagonist is administered with at least one active ingredient selected from the group consisting of protein, protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars, sugar derivatives, vitamins, hydroxy acids, retinol, tocopherol, ceramides, essential oils, and salicylic acid.

D²³
109. (Amended) The method of Claim 119, wherein said substance P antagonist is administered together with at least one active ingredient that elicits an irritant side effect.

D²⁴
111. (Amended) The method of Claim 119, wherein said substance P antagonist is contained in a cosmetically-acceptable medium.

D²⁵
113. (Amended) The method of Claim 119, wherein capsaicin-sensitive skin is skin that is characterized by at least one symptom selected from the group consisting of tingling, burning, itching, and erythema after topical application of capsaicin.

D25
cont.
114. (Amended) The method of Claim 119, wherein said at least one symptom is observed between 3 and 20 minutes after capsaicin application.

✓
Kindly add new claims 115-120 as follows:

D26
115. (New) A cosmetic or dermatological method for treating sensitive skin of an individual in need of such treatment, such sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, the method comprising topically applying to said sensitive skin a cosmetic/dermatological composition which comprises an effective amount of at least one active ingredient which causes the release of substance P in sensitive skin and an amount of at least one substance P antagonist effective to attenuate or eliminate such release of substance P, formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

NO
116. (New) A cosmetic or dermatological method for treating sensitive skin of an individual in need of such treatment, said sensitive skin having such amount of substance P already released therein as to cause neurogenic manifestations of dyesthesia caused by the release of substance P therein, said sensitive skin being characterized by exhibiting at least one symptom selected from the group consisting of tingling, prickly, itching, pruritus, overheating, discomfort, tugging sensations, desquamation and erythema; said method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition and wherein said effective amount of said at

least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

117. (New) A cosmetic or dermatological method for treating sensitive, but not allergic, skin of an individual in need of such treatment, such sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, said method comprising topically applying to said sensitive skin a cosmetic/dermatological composition which comprises an effective amount of at least one active ingredient which causes the release of substance P in sensitive skin and an amount of at least one substance P antagonist effective to attenuate or eliminate such release of substance P, formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

118. (New) A cosmetic or dermatological method for treating sensitive, but not allergic, skin of an individual in need of such treatment, said sensitive skin said sensitive skin having such amount of substance P already released therein as to cause neurogenic manifestations of dyesthesia caused by the release of substance P, said method comprising topically applying to said sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said effective amount of said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

119. (New) A cosmetic or dermatological method for treating capsaicin-sensitive skin of an individual in need of such treatment, said sensitive skin having or developing neurogenic manifestations of dyesthesia caused by the release of substance P therein, said method comprising topically applying to said capsaicin-sensitive skin an a cosmetic/dermatological composition which comprises an effective amount of at least one active ingredient which causes the release of substance P in sensitive skin and an amount of at least one substance P antagonist effective to attenuate or eliminate such release of substance P, formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.

120. (New) A cosmetic or dermatological method for treating capsaicin-sensitive skin of an individual in need of such treatment, said sensitive skin having such amount of substance P already released therein as to cause neurogenic manifestations of dyesthesia caused by the release of substance P therein, said method comprising topically applying to said capsaicin-sensitive skin an effective amount of at least one substance P antagonist-containing composition, and wherein said at least one substance P antagonist is formulated into a topically applicable cosmetically- or dermatologically-acceptable medium therefor.
